Abstract
Improvement in the clinical outcome of lung cancer is likely to be achieved by identification of the molecular events that underlie its pathogenesis. Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells. Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and subcutaneous tumours in nude mice. The EML4–ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examined; these individuals were distinct from those harbouring mutations in the epidermal growth factor receptor gene. Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic molecular marker in NSCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal, A. et al. Cancer statistics, 2006. CA Cancer J. Clin. 56, 106–130 (2006)
Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92–98 (2002)
Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004)
Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004)
Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001)
Pao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004)
Yoshizuka, N. et al. An alternative transcript derived from the Trio locus encodes a guanosine nucleotide exchange factor with mouse cell-transforming potential. J. Biol. Chem. 279, 43998–44004 (2004)
Hatanaka, H. et al. Transforming activity of purinergic receptor P2Y, G-protein coupled, 2 revealed by retroviral expression screening. Biochem. Biophys. Res. Commun. 356, 723–726 (2007)
Choi, Y. L. et al. Identification of a constitutively active mutant of JAK3 by retroviral expression screening. Leuk. Res. 31, 203–209 (2007)
Fujiwara, S. et al. Transforming activity of the lymphotoxin-β receptor revealed by expression screening. Biochem. Biophys. Res. Commun. 338, 1256–1262 (2005)
Pollmann, M. et al. Human EML4, a novel member of the EMAP family, is essential for microtubule formation. Exp. Cell Res. 312, 3241–3251 (2006)
Eichenmuller, B., Everley, P., Palange, J., Lepley, D. & Suprenant, K. A. The human EMAP-like protein-70 (ELP70) is a microtubule destabilizer that localizes to the mitotic apparatus. J. Biol. Chem. 277, 1301–1309 (2002)
Smith, T. F., Gaitatzes, C., Saxena, K. & Neer, E. J. The WD repeat: a common architecture for diverse functions. Trends Biochem. Sci. 24, 181–185 (1999)
Morris, S. W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263, 1281–1284 (1994)
Shiota, M. et al. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9, 1567–1574 (1994)
Pulford, K., Morris, S. W. & Turturro, F. Anaplastic lymphoma kinase proteins in growth control and cancer. J. Cell. Physiol. 199, 330–358 (2004)
Galkin, A. V. et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl Acad. Sci. USA 104, 270–275 (2007)
Donella-Deana, A. et al. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry 44, 8533–8542 (2005)
Hernandez, L. et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALKXL chimeric gene with transforming activity. Am. J. Pathol. 160, 1487–1494 (2002)
Palacious, R. & Steinmetz, M. IL-3 dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.. Cell 41, 727–734 (1985)
Kaul, K. L. Molecular detection of Mycobacterium tuberculosis: impact on patient care. Clin. Chem. 47, 1553–1558 (2001)
Marzec, M. et al. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab. Invest. 85, 1544–1554 (2005)
Li, R. et al. Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. J. Med. Chem. 49, 1006–1015 (2006)
Watanabe, S., Itoh, T. & Arai, K. JAK2 is essential for activation of c-fos and c-myc promoters and cell proliferation through the human granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells. J. Biol. Chem. 271, 12681–12686 (1996)
Duyster, J., Bai, R. Y. & Morris, S. W. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20, 5623–5637 (2001)
Onishi, M. et al. Applications of retrovirus-mediated expression cloning. Exp. Hematol. 24, 324–329 (1996)
Yamashita, Y. et al. Sak serine/threonine kinase acts as an effector of Tec tyrosine kinase. J. Biol. Chem. 276, 39012–39020 (2001)
Acknowledgements
We thank R. Moriuchi for suggestions.
Author Contributions M.S. and Y.L.C. contributed equally to this work. M.S., S.-i.F., H.W. and H.H. constructed the cDNA library and screened for transforming genes. Y.L.C. sequenced the EML4–ALK cDNA and conducted the experiments with BA/F3 cells. Y.Y. and S.T. searched for EGFR and KRAS mutations. M.E., S.I., K.K., M.B., S.O., S.T., Y.I. and H.A. performed RT–PCR for EML4–ALK transcripts in cancer specimens. T.N., Y. Sohara, Y. Sugiyama and H.M. designed the overall project, and H.M. wrote the manuscript. All authors discussed the results and commented on the manuscript.
The nucleotide sequences of EML4–ALK variant 1 and variant 2 cDNA have been deposited in DDBJ, EMBL and GenBank under the accession numbers AB274722 and AB275889, respectively.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests.
Supplementary information
Supplementary Informationn
This file contains Supplementary Data, Supplementary Table 1 and Supplementary Figures 1-4 with Legends. (PDF 886 kb)
Rights and permissions
About this article
Cite this article
Soda, M., Choi, Y., Enomoto, M. et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007). https://doi.org/10.1038/nature05945
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature05945
This article is cited by
-
Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature
Diagnostic Pathology (2024)
-
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Biomarker Research (2024)
-
New clinical trial design in precision medicine: discovery, development and direction
Signal Transduction and Targeted Therapy (2024)
-
Recent nanotechnological aspects and molecular targeting strategies for lung cancer therapy
Journal of Nanoparticle Research (2024)
-
Downregulated CDH3 is correlated with a better prognosis for LUAD and decreases proliferation and migration of lung cancer cells
Genes & Genomics (2024)